Home > Boards > US Listed > Medical - Drugs > Dr. Reddy's Laboratories Limited (RDY)

It's ringfence time at Reddy's

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
buhg1b Member Profile
 
Followed By 8
Posts 737
Boards Moderated 0
Alias Born 05/03/07
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/1/2021 10:18:54 AM
Dr. Reddy's requested by India to give more data for Sputnik V approval Seeking Alpha - 2/25/2021 11:07:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/22/2021 7:14:42 AM
Dr. Reddy's launches generic Prevacid SoluTab tablets in U.S. Seeking Alpha - 2/22/2021 3:06:02 AM
Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market Business Wire - 2/22/2021 1:13:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/19/2021 8:25:51 AM
Dr. Reddy's seeks emergency use nod for Sputnik V in India Seeking Alpha - 2/19/2021 6:10:52 AM
Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V Business Wire - 2/19/2021 5:45:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/18/2021 8:09:04 AM
Dr. Reddy's launches generic Prolixin tablets in U.S. Seeking Alpha - 2/18/2021 3:36:49 AM
Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market Business Wire - 2/18/2021 1:50:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/17/2021 6:31:19 AM
Dr. Reddy's launches generic capecitabine tablets in U.S. Seeking Alpha - 2/17/2021 5:21:18 AM
Dr. Reddy's Laboratories Announces the Launch of Capecitabine Tablets, USP in the U.S. Market Business Wire - 2/17/2021 5:11:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/3/2021 11:32:50 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/2/2021 7:16:34 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/2/2021 7:06:51 AM
Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market Business Wire - 2/2/2021 4:20:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/29/2021 8:10:04 AM
Dr. Reddy’s Q3 & 9M FY21 Financial Results Business Wire - 1/29/2021 4:37:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/27/2021 9:08:09 AM
Dr. Reddy’s and GRA announces Avigan Pivotal Studies Update Business Wire - 1/27/2021 5:02:00 AM
Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India Business Wire - 1/15/2021 12:33:00 PM
Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India Business Wire - 1/11/2021 10:25:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/11/2021 8:48:27 AM
buhg1b   Thursday, 05/08/08 11:50:59 AM
Re: None
Post # of 19 
It's ringfence time at Reddy's
C Chitti Pantulu / DNA MONEY
Wednesday, 07 May , 2008, 09:52


The Orchid Chemicals lesson has not been lost on Dr Reddy's Laboratories.

More India business stories

The Hyderabad-based company's promoters are seeking to ringfence India's second largest pharma player.

Dr Reddy's vice-chairman and chief executive G V Prasad told DNA Money that the company's board, at a meeting on January 25, had approved a preferential issue of share warrants up to 5% of the existing equity of DRL, exercisable into an equal number of equity shares.

"We have not exercised that option because we haven't approached shareholders yet," he said, adding that the option may be looked at now.

The Bombay Stock Exchange's records show that promoters held 25.14% in Dr Reddy's as on March 31, 2008.

Asked about hostile bids, Prasad said the management was hoping to create good shareholder value and through this, keep such threats low.

"The only way (to avoid hostile bids) is to keep the share price from dipping. It shouldn't become low enough to attract such bids," he said.

But Dr Reddy's shares haven't exactly been soaring on the BSE.

The shares fell 8.49% to Rs 643.80 on Tuesday. After touching a high of Rs 747 on January 2, the company's shares have dipped 14% to date. Prasad blames the problems being faced by Betapharm, the German generics maker it acquired in 2006 to the drag on Dr Reddy's. Price reforms introduced by Germany in April have made life difficult.

The other factors that have hurt its performance are increasing rebates to insurance companies and a change in the composition of Betapharm's top products.

More India business stories

Prasad, however, felt that the downswing is temporary and won't hurt the company in the long term.

http://sify.com/finance/fullstory.php?id=14668506

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences